Jan 11, 2024 / 05:00PM GMT
Eric Joseph JPMorgan-Moderator
All right. Good morning. I'm Eric Joseph, senior biotech analyst at JPMorgan. And our next presenting company this morning is C4 Therapeutics. Presenting on behalf of the company is CEO, Andrew Hirsch, there's a Q&A session after the presentation, just raise your hand, we'll bring a mic over to you before asking your question and for folks tuning in via the webcast feel free to submit questions via the portal.
So with that, Andrew, thanks for joining us.
Andrew Hirsch C4 Therapeutics Inc-CEO
Great. Thank you, Eric, and thanks to JPMorgan for having us here today. So before I begin, I wanted to just comment that I'll be making forward-looking statements today. Obviously, those are subject to various risks and uncertainties, and you should look at the risk factors section of our SEC filings to understand what those risks and uncertainties are.
So for those of you new to C4, C4 was a recognized leader in the world of targeted protein degradation. In fact, one of the pioneers. We were started in
C4 Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers